Name: Net Profit Margin

Definition: Net profit margin shows how much profit remains after paying all costs — including operating expenses, interest, and taxes — for every dollar of sales. A higher margin means the business is efficient and keeps more of its sales as bottom-line profit. Falling margins may signal rising costs or pricing pressure.

Interpretation:
• In '2021', CLDX's net profit margin was -1516.0%, measuring the overall profitability of the company. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at -112.6%.
• In '2022', CLDX's net profit margin was -4765.6%, measuring the overall profitability of the company. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at -95.7%. Industry average increased by 17.0% compared to previous year.
• In '2023', CLDX's net profit margin was -2054.8%, measuring the overall profitability of the company. The increase since '2022' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at -26.6%. Industry average increased by 69.1% compared to previous year.
• In '2024', CLDX's net profit margin was -2248.8%, measuring the overall profitability of the company. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at -105.1%. Industry average declined by 78.5% from previous year.
Overall, CLDX's net profit margin has been volatile but showed a downward trend over the past 4 years.

Formula: Net Profit Margin = Net Income / Revenue

Good Range: Ranges 5%-20% for many industries.